



**S5 Fig. Validation of CYR61 and TAZ antibodies specificity.** **A.** Western-blot analysis was performed to test the CYR61 and TAZ antibodies specificity on the breast cancer cell lines MDA213 and MCF7. A band of ~42KDa and ~40KDa was observed when using CYR61 and TAZ antibodies, respectively.  $\beta$ -Actin antibody (~50 KDa) was used as a loading control. **B.** Breast cancer and **C.** placenta tissue sections used as used as positive controls of CYR61 and TAZ antibodies, respectively. Magnification 100X.